Ensminger S M, Billing J S, Morris P J, Wood K J
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
J Heart Lung Transplant. 2000 Nov;19(11):1039-46. doi: 10.1016/s1053-2498(00)00195-9.
The degree of transplant arteriosclerosis in murine cardiac allografts is difficult to assess. Aortic allografts represent an alternative model for evaluating the impact of novel transplant strategies on transplant arteriosclerosis in which the vascular changes can be quantified easily. However, it remains controversial as to whether vascular lesions seen in this model are equivalent to those that develop in solid-organ transplants. The aim of this study was to develop a model of combined cardiac and aortic transplantation to allow more precise quantification of transplant arteriosclerosis and to establish a correlation between the lesions that develop in the 2 types of graft.
CBA (H2(k)) recipients received a C57BL/10 (H2(b)) cervical cardiac allograft on Day 0 and a C57BL/10 (H2(b)) abdominal aortic allograft on Day 1. Recipients were treated with anti-CD154 mAb (MR1) on Days 0, 2, and 4. We performed histology and morphometric measurements for both grafts 30 days after transplantation.
We observed significant intimal proliferation in both the cervical cardiac and abdominal aortic allografts from recipients treated with anti-CD154 mAb (heart, 64% +/- 9%; aorta, 67% +/- 8%; n = 5). Abdominal aortic grafts transplanted alone into anti-CD154-treated recipients developed a degree of transplant arteriosclerosis equivalent to that seen in the aortic grafts of the combined group (aorta alone, 68% +/- 9%, vs aorta + heart, 67% +/- 8%; n = 5).
This combined cardiac and aortic transplant model permitted quantitative assessment of transplant arteriosclerosis while monitoring graft survival by cardiac palpation. Furthermore, development of transplant arteriosclerosis was equivalent in abdominal aortic allografts either in the presence or absence of an additional solid- organ transplant.
小鼠心脏同种异体移植中移植动脉硬化的程度难以评估。主动脉同种异体移植是评估新型移植策略对移植动脉硬化影响的另一种模型,其中血管变化易于量化。然而,该模型中所见的血管病变是否等同于实体器官移植中发生的病变仍存在争议。本研究的目的是建立一种心脏和主动脉联合移植模型,以更精确地量化移植动脉硬化,并确定两种类型移植物中发生的病变之间的相关性。
CBA(H2(k))受体在第0天接受C57BL/10(H2(b))颈部心脏同种异体移植,并在第1天接受C57BL/10(H2(b))腹部主动脉同种异体移植。受体在第0、2和4天接受抗CD154单克隆抗体(MR1)治疗。移植后30天对两种移植物进行组织学和形态测量。
我们观察到接受抗CD154单克隆抗体治疗的受体的颈部心脏和腹部主动脉同种异体移植中均有显著的内膜增生(心脏,64%±9%;主动脉,67%±8%;n = 5)。单独移植到接受抗CD154治疗的受体中的腹部主动脉移植物发生的移植动脉硬化程度与联合组主动脉移植物中所见的程度相当(单独主动脉,68%±9%,对比主动脉+心脏,67%±8%;n = 5)。
这种心脏和主动脉联合移植模型允许在通过心脏触诊监测移植物存活的同时对移植动脉硬化进行定量评估。此外,无论是否存在额外的实体器官移植,腹部主动脉同种异体移植中移植动脉硬化的发展是相当的。